The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche/Genentech
 
Consulting or Advisory Role - ABBVIE; AstraZeneca; Blueprint Medicines; BOEHRINGER INGELHEIM; BRISTOL-MYERS SQUIBB; Guardant Health; JANSSEN; LILLY; MERCK KGaA; MERCK SHARP & DOHME; NOVARTIS; PFIZER; Roche; SAMSUNG; TAKEDA
Speakers' Bureau - AstraZeneca; BRISTOL-MYERS SQUIBB; LILLY; MEDSCAPE; Merck Sharp & Dohme; NOVARTIS; PFIZER; prIME ONCOLOGY; ROCHE; TAKEDA; touchIME
Research Funding - Grant for Oncology Innovation; Merck
Other Relationship - GRÍFOLS
Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC).
 
Delvys Rodriguez-Abreu
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Roche
Speakers' Bureau - Bristol-Myers Squibb; MSD; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Roche
 
Steven Francis Powell
Consulting or Advisory Role - Bristol-Myers Squibb (Inst)
Research Funding - Actuate Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Vyriad (Inst)
 
Maximilian Hochmair
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Roche; Takeda
 
Shirish M. Gadgeel
Honoraria - AstraZeneca; Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech/Roche; Novocure; Takeda; Xcovery
Research Funding - Aeglea Biotherapeutics (Inst); ARIAD/Takeda (Inst); Astellas Pharma (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Lycera (Inst); Merck; Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Merck
Other Relationship - AstraZeneca
 
Emilio Esteban
Travel, Accommodations, Expenses - Pfizer/EMD Serono; Pfizer/EMD Serono
 
Enriqueta Felip
No Relationships to Disclose
 
Giovanna Speranza
No Relationships to Disclose
 
Manuel Dómine Gomez
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Lilly; Pfizer; Roche
 
Susanna Y. Cheng
Honoraria - Merck
Consulting or Advisory Role - AstraZeneca/MedImmune; Merck
 
Helge Bischoff
No Relationships to Disclose
 
Nir Peled
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Pfizer (Inst); Roche/Genentech (Inst)
 
Martin Reck
No Relationships to Disclose
 
Rina Hui
Honoraria - AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Roche
Travel, Accommodations, Expenses - Novartis; Roche
 
Edward B. Garon
Consulting or Advisory Role - Dracen; EMD Serono; GlaxoSmithKline; Novartis
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst)
 
Michael J. Boyer
Honoraria - AstraZeneca; Boehringer Ingelheim (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst)
Research Funding - Amgen (Inst); Ascentage Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Benitec Biopharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Janssen (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Genentech/Roche; Merck Sharp & Dohme
 
Takayasu Kurata
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly; MSD Oncology; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst)
 
Jing Yang
Employment - Merck
 
Tuba Bas
Employment - Fiore Healthcare Advisors (I); Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
Consulting or Advisory Role - Fiore Healthcare Advisors (I)
Travel, Accommodations, Expenses - Fiore Healthcare Advisors (I); Merck Sharp & Dohme
 
Fabricio G. Souza
Employment - Merck Sharp & Dohme
 
Marina Chiara Garassino
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; MSD Oncology; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Incyte; Inivata; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Seagen; Takeda; Tiziana Life Sciences
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Celgene; Incyte; Lilly; MSD Oncology; Otsuka; Roche; Takeda
Research Funding - AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche